Mast cells promote atherosclerosis by inducing both an atherogenic lipid profile and vascular inflammation

Journal of Cellular Biochemistry

Volumn 109, Issue 3, 2010, Pages 615-623

  Heikkilä, Hanna M ^a   Trosien, Julia ^a   Metso, Jari ^b   Jauhiainen, Matti ^b   Pentikäinen, Markku O ^a   Kovanen, Petri T ^a   Lindstedt, Ken A ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Atherosclerosis; Lipids; Mast cell; Mouse model

Indexed keywords

APOLIPOPROTEIN B; INTERCELLULAR ADHESION MOLECULE 1; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHOLIPID TRANSFER PROTEIN; PRE BETA HIGH DENSITY LIPOPROTEIN; SERUM AMYLOID A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SINUS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOOD INTAKE; LIPOPROTEIN METABOLISM; MALE; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VASCULITIS;

ANIMALS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; FEMALE; LIPID METABOLISM; LIPOPROTEINS; MALE; MAST CELLS; MICE; MICE, TRANSGENIC; RECEPTORS, LDL; VASCULITIS;

MUS;

EID: 74949139509     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22443     Document Type: Article

References (53)

1. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ. 2004. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24:2181-2187.
2. Barlage S, Frohlich D, Bottcher A, Jauhiainen M, Muller HP, Noetzel F, Rothe G, Schutt C, Linke RP, Lackner KJ, Ehnholm C, Schmitz G. 2001. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 42:281-290.
3. Bot I, de Jager SC, Zernecke A, Lindstedt KA, van Berkel TJ, Weber C, Biessen EA. 2007. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation 115:2516-2525.
4. Boyce JA, Mellor EA, Perkins B, Lim YC, Luscinskas FW. 2002. Human mast cell progenitors use alpha4-integrin, VCAM-1, and PSGL-1 E-selectin for adhesive interactions with human vascular endothelium under flow conditions. Blood 99:2890-2896.
5. Castells MC, Friend DS, Bunnell CA, Hu X, Kraus M, Osteen RT, Austen KF. 1996. The presence of membrane-bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis. J Allergy Clin Immunol 98:831-840.
6. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. 1988. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335:88-89.
7. Copeland NG, Gilbert DJ, Cho BC, Donovan PJ, Jenkins NA, Cosman D, Anderson D, Lyman SD, Williams DE. 1990. Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell 63:175-183.
8. Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA, Menchaca DM, Gringeri AJ, Schwartz LB, Galli SJ. 1996. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 183:2681-2686.
9. Damen J, Regts J, Scherphof G. 1982. Transfer of [14C]phosphatidylcholine between liposomes and human plasma high density lipoprotein. Partial purification of a transfer-stimulating plasma factor using a rapid transfer assay. Biochim Biophys Acta 712:444-452.
10. Dileepan KN, Johnston TP, Li Y, Tawfik O, Stechschulte DJ. 2004. Deranged aortic intima-media thickness, plasma triglycerides and granulopoiesis in Sl/ Sl(d) mice. Mediators Inflamm 13:335-341.
11. Folch J, Lees M, Sloane Stanley GH. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497-509.
12. Forman MB, Oates JA, Robertson D, Robertson RM, Roberts LJ, II, Virmani R. 1985. Increased adventitial mast cells in a patient with coronary spasm. N Engl J Med 313:1138-1141.
13. Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. 2005. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 167:835-848.
14. Haley KJ, Lilly CM, Yang JH, Feng Y, Kennedy SP, Turi TG, Thompson JF, Sukhova GH, Libby P, Lee RT. 2000. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 102:2185-2189.
15. Jauhiainen M, Ehnholm C. 2005. Determination of human plasma phospholipid transfer protein mass and activity. Methods 36:97-101.
16. Kaartinen M, Penttilä A, Kovanen PT. 1994. Mast cells of two types differing in neutral protease composition in the human aortic intima. Demonstration of tryptase- and tryptase/chymase-containing mast cells in normal intimas, fatty streaks, and the shoulder region of atheromas. Arterioscler Thromb 14:966-972.
17. Kalsner S, Richards R. 1984. Coronary arteries of cardiac patients are hyperreactive and contain stores of amines: A mechanism for coronary spasm. Science 223:1435-1437.
18. Kanbe N, Kurosawa M, Miyachi Y, Kanbe M, Saitoh H, Matsuda H. 2000. Nerve growth factor prevents apoptosis of cord blood-derived human cultured mast cells synergistically with stem cell factor. Clin Exp Allergy 30:1113-1120.
19. Kinoshita T, Sawai N, Hidaka E, Yamashita T, Koike K. 1999. Interleukin-6 directly modulates stem cell factor-dependent development of human mast cells derived from CD34(+) cord blood cells. Blood 94:496-508.
20. Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. 1991. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol 146:1410-1415.
21. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. 1999. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 94:2333-2342.
22. Kitamura Y, Ito A. 2005. Mast cell-committed progenitors. Proc Natl Acad Sci USA 102:11129-11130.
23. Kitamura Y, Go S, Hatanaka K. 1978. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52:447-452.
24. Kovanen PT. 1993. The mast cell-A potential link between inflammation and cellular cholesterol deposition in atherogenesis. Eur Heart J 14(Suppl K):105-117.
25. Kubes P, Granger DN. 1996. Leukocyte-endothelial cell interactions evoked by mast cells. Cardiovasc Res 32:699-708.
26. Laine P, Kaartinen M, Penttilä A, Panula P, Paavonen T, Kovanen PT. 1999. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 99:361-369.
27. Lappalainen J, Lindstedt KA, Kovanen PT. 2007. A protocol for generating high numbers of mature and functional human mast cells from peripheral blood. Clin Exp Allergy 37:1404-1414.
28. Lätti S, Leskinen M, Shiota N, Wang Y, Kovanen PT, Lindstedt KA. 2003. Mast cell-mediated apoptosis of endothelial cells in vitro: A paracrine mechanism involving TNF-alpha-mediated down-regulation of bcl-2 expression. J Cell Physiol 195:130-138.
29. Lee M, Lindstedt LK, Kovanen PT. 1992. Mast cell-mediated inhibition of reverse cholesterol transport. Arterioscler Thromb 12:1329-1335.
30. Lee M, Kovanen PT, Tedeschi G, Oungre E, Franceschini G, Calabresi L. 2003a. Apolipoprotein composition and particle size affect HDL degradation by chymase: Effect on cellular cholesterol efflux. J Lipid Res 44:539-546.
31. Lee M, Metso J, Jauhiainen M, Kovanen PT. 2003b. Degradation of phospholipid transfer protein (PLTP) and PLTP-generated pre-beta-high density lipoprotein by mast cell chymase impairs high affinity efflux of cholesterol from macrophage foam cells. J Biol Chem 278:13539-13545.
32. Lee-Rueckert M, Vikstedt R, Metso J, Jauhiainen M, Kovanen PT. 2008. Association of cholesteryl ester transfer protein with HDL particles reduces its proteolytic inactivation by mast cell chymase. J Lipid Res 49:358-368.
33. Leskinen M, Wang Y, Leszczynski D, Lindstedt KA, Kovanen PT. 2001. Mast cell chymase induces apoptosis of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21:516-522.
34. Leskinen MJ, Lindstedt KA, Wang Y, Kovanen PT. 2003. Mast cell chymase induces smooth muscle cell apoptosis by a mechanism involving fibronectin degradation and disruption of focal adhesions. Arterioscler Thromb Vasc Biol 23:238-243.
35. Lindstedt KA, Kovanen PT. 2004. Mast cells in vulnerable coronary plaques: Potential mechanisms linking mast cell activation to plaque erosion and rupture. Curr Opin Lipidol 15:567-573.
36. Lindstedt KA, Mäyränpää MI, Kovanen PT. 2007. Mast cells in vulnerable atherosclerotic plaques-A view to a kill. J Cell Mol Med 11:739-758.
37. Lo JC, Wang Y, Tumanov AV, Bamji M, Yao Z, Reardon CA, Getz GS, Fu YX. 2007. Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 316:285-288.
38. Matsuzawa S, Sakashita K, Kinoshita T, Ito S, Yamashita T, Koike K. 2003. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol 170:3461-3467.
39. Mäyränpää MI, Heikkilä HM, Lindstedt KA, Walls AF, Kovanen PT. 2006. Desquamation of human coronary artery endothelium by human mast cell proteases: Implications for plaque erosion. Coron Artery Dis 17:611-621.
40. Nagle DL, Kozak CA, Mano H, Chapman VM, Bucan M. 1995. Physical mapping of the Tec and Gabrb1 loci reveals that the Wsh mutation on mouse chromosome 5 is associated with an inversion. Hum Mol Genet 4:2073-2079.
41. Nakano T, Waki N, Asai H, Kitamura Y. 1989. Different repopulation profile between erythroid and nonerythroid progenitor cells in genetically anemic W/Wv mice after bone marrow transplantation. Blood 74:1552-1556.
42. Ochi H, Hirani WM, Yuan Q, Friend DS, Austen KF, Boyce JA. 1999. T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 190:267-280.
43. Rottem M, Okada T, Goff JP, Metcalfe DD. 1994. Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/Fc epsilon RI-cell population. Blood 84:2489-2496.
44. Saito H, Ebisawa M, Tachimoto H, Shichijo M, Fukagawa K, Matsumoto K, Iikura Y, Awaji T, Tsujimoto G, Yanagida M, Uzumaki H, Takahashi G, Tsuji K, Nakahata T. 1996. Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol 157:343-350.
45. Schlitt A, Bickel C, Thumma P, Blankenberg S, Rupprecht HJ, Meyer J, Jiang XC. 2003. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 23:1857-1862.
46. Schlitt A, Liu J, Yan D, Mondragon-Escorpizo M, Norin AJ, Jiang XC. 2005. Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. Biochim Biophys Acta 1733:187-191.
47. Skogsberg J, Lundstrom J, Kovacs A, Nilsson R, Noori P, Maleki S, Kohler M, Hamsten A, Tegner J, Bjorkegren J. 2008. Transcriptional profiling uncovers a network of cholesterol-responsive atherosclerosis target genes. PLoS Genet 4:e1000036.
48. Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, MacFarlane LA, Mallen-St Clair J, Shi GP. 2007. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 13:719-724.
49. Tono T, Tsujimura T, Koshimizu U, Kasugai T, Adachi S, Isozaki K, Nishikawa S, Morimoto M, Nishimune Y, Nomura S. 1992. c-kit Gene was not transcribed in cultured mast cells of mast cell-deficient Wsh/Wsh mice that have a normal number of erythrocytes and a normal c-kit coding region. Blood 80:1448-1453.
50. Tsai M, Tam SY, Wedemeyer J, Galli SJ. 2002. Mast cells derived from embryonic stem cells: A model system for studying the effects of genetic manipulations on mast cell development, phenotype, and function in vitro and in vivo. Int J Hematol 75:345-349.
51. Valenta DT, Ogier N, Bradshaw G, Black AS, Bonnet DJ, Lagrost L, Curtiss LK, Desrumaux CM. 2006. Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioscler Thromb Vasc Biol 26:1572-1578.
52. van Haperen R, van Tol A, Vermeulen P, Jauhiainen M, van Gent T, van den Berg P, Ehnholm S, Grosveld F, van der Kamp A, de Crom R. 2000. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 20:1082-1088.
53. Vikstedt R, Ye D, Metso J, Hildebrand RB, Van Berkel TJ, Ehnholm C, Jauhiainen M, Van Eck M. 2007. Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development. Arterioscler Thromb Vasc Biol 27:578-586.